Photo of David M. Dorfman,  MD, PhD

David M. Dorfman, MD, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 732-7518
Fax: (617) 731-4872


ddorfman@bwh.harvard.edu

David M. Dorfman, MD, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Professor, Pathology, Harvard Medical School
  • Pathologist, Pathology, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research focuses on the diagnosis and analysis of hematopoietic neoplasms, particularly those of the immune system, to understand the relationship of these neoplasms to their normal cellular counterparts, and to identify new biological markers and approaches for their diagnosis, subtyping, and treatment. This work has included studies of a number of important biomarkers for the characterization of B cell and T cell neoplasms and other hematopoietic neoplasms, a number of which are widely utilized in clinical practice, and include: immune checkpoint receptor Programmed Death-1 (PD-1), including the first report that it is a marker of angioimmunoblastic T cell lymphoma, as well as a study of PD-L1 and PD-L2 ligands, which found that they are expressed in epithelial malignancies and play a role in attenuating the anti-tumor immune response, the foundational work for checkpoint inhibitor blockade as a treatment for a wide variety of solid tumors; chemokine receptors, which are involved in chemotaxis and cell migration of immune system cells, including neoplastic cells, in B cell and T cell neoplasms; OX-2 membrane glycoprotein (CD200), an immunomodulatory molecule, in angioimmunoblastic T cell lymphoma and a subset of B cell lymphomas, including hairy cell leukemia and mediastinal large B cell lymphoma, hairy cell leukemia and lymphoplasmacytic lymphoma; T cell transcription factors in T cell and B cell neoplasms; EZH2 methytransferase, which contributes to tumor development in hematopoietic malignancies, in T cell and B cell neoplasms as well as histiocytic and dendritic neoplasms and Hodgkin lymphomas; CD5 in B cell and T cell neoplasms and thymic epithelial neoplasms.

Publications

Powered by Harvard Catalyst
  • Patel SS, Dorfman DM. Leukemic-phase progression of aleukemic mast cell leukemia. Blood 2018; 131:2406. PubMed
  • Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun 2018; 9:2024. PubMed
  • Tian X, Xu J, Fletcher C, Hornick JL, Dorfman DM. Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling. Mod Pathol 2018. PubMed
  • Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J. Realgar nanoparticles versus ATO arsenic compounds induce in┬ávitro and in┬ávivo activity against multiple myeloma. British Journal of Haematology 2017; 179:756-771. PubMed
  • Shanmugam V, Dorfman DM. An unusual case of chronic lymphocytic leukemia/small lymphocytic lymphoma with nodular morphology. Leuk Lymphoma 2017; 58:2014-2016. PubMed
  • Dorfman DM, Morgan EA, Pelton A, Unitt C. T-cell transcription factor GATA-3 is an immunophenotypic marker of acute leukemias with T-cell differentiation. Hum Pathol 2017; 65:166-174. PubMed
  • Mason EF, Pozdnyakova O, Li B, Dudley G, Dorfman DM. Flow Cytometric Patterns of CD200 and CD1d Expression Distinguish CD10-Negative, CD5-Negative Mature B-Cell Lymphoproliferative Disorders. Am J Clin Pathol 2017; 148:33-41. PubMed
  • Tian X, Pelton A, Shahsafaei A, Dorfman DM. . Differential expression of Enhancer of Zeste Homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1/2 and MYC in aggressive B-cell lymphomas. Mod Pathol 2016; 29:1050-1057.